Lund (Sweden) - Immunovia invites to a teleconference (in English) for investors, analysts and media on February 14, at 5:30 - 6:30 p.m. CET. Immunovia will publish the company's Full Year Report 2018 for the period January - December 2018 on Thursday, February 14, at 5:05 p.m. CET.
Mats Grahn, CEO will present Immunovia and comment on the Full Year Report 2018 followed by a Q&A-session. Please call in a few minutes in advance.
To attend, please dial-in at one of the numbers below:
For questions or interview bookings:
There will be an MP3-file available at Immunovia's webpage under Investors/audio-galley (https://immunovia.com/investors/audio-gallery/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
(c) 2019 Cision. All rights reserved., source Press Releases - English